An Lin

No. 420, Fuma Road
Fuzhou, 350014, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Bioinformatic and experimental analysis reveals ITGA5 as a driver of ovarian clear cell carcinoma progression and platinum resistance.

Bioinformatic and experimental analysis reveals ITGA5 as a driver of ovarian clear cell carcinoma progression and platinum resistance.

Journal: 3 Biotech

Published: January 12, 2026

Niraparib treatment patterns and outcomes in first-line maintenance therapy for ovarian cancer: The RENI-1 study.

Niraparib treatment patterns and outcomes in first-line maintenance therapy for ovarian cancer: The RENI-1 study.

Journal: Chinese medical journal

Published: December 23, 2025

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.

Journal: CA: a cancer journal for clinicians

Published: September 15, 2025

Correction: RNLS promotes ovarian cancer growth and inhibits ferroptosis via mediating STAT3.

Correction: RNLS promotes ovarian cancer growth and inhibits ferroptosis via mediating STAT3.

Journal: Frontiers in oncology

Published: September 02, 2025

miR-101-3p represses the migratory and invasive abilities of ovarian cancer cells.

miR-101-3p represses the migratory and invasive abilities of ovarian cancer cells.

Journal: BMC cancer

Published: July 02, 2025

Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study.

Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 25, 2025

RNLS promotes ovarian cancer growth and inhibits ferroptosis via mediating STAT3.

RNLS promotes ovarian cancer growth and inhibits ferroptosis via mediating STAT3.

Journal: Frontiers in oncology

Published: April 01, 2025

Adverse Event Management in Patients with Platinum-Resistant Ovarian Cancer Treated with Niraparib and Anlotinib: Updates from the Phase II, Multi-Center ANNIE Study.

Adverse Event Management in Patients with Platinum-Resistant Ovarian Cancer Treated with Niraparib and Anlotinib: Updates from the Phase II, Multi-Center ANNIE Study.

Journal: Therapeutics and clinical risk management

Published: March 31, 2025

Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial.

Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial.

Journal: Nature medicine

Published: November 17, 2023

Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial.

Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial.

Journal: JAMA oncology

Published: July 13, 2023

A novel combination of niraparib and anlotinib in platinum-resistant ovarian cancer: Efficacy and safety results from the phase II, multi-center ANNIE study.

A novel combination of niraparib and anlotinib in platinum-resistant ovarian cancer: Efficacy and safety results from the phase II, multi-center ANNIE study.

Journal: EClinicalMedicine

Published: August 05, 2022

A prognostic model using FIGO 2018 staging and MRI-derived tumor volume to predict long-term outcomes in patients with uterine cervical squamous cell carcinoma who received definitive radiotherapy.

A prognostic model using FIGO 2018 staging and MRI-derived tumor volume to predict long-term outcomes in patients with uterine cervical squamous cell carcinoma who received definitive radiotherapy.

Journal: World journal of surgical oncology

Published: July 24, 2022

Showing 1-12 of 23

Last Updated: 09/26/2026